

Risk factor		Strength of evidence	Literature support, references
Cardiovascular fitness	• Increased exercise tolerance	Level 1b	(Gass et al. 1980, DiCarlo et al. 1983, DiCarlo 1988, Hjeltnes and Wallberg-Henriksson 1998, Jacobs et al. 2002, de Groot et al. 2003, Sutbeyaz et al. 2005)
	• Increased VO _{2max}	Level 1b	(Gass et al. 1980, DiCarlo et al. 1983, Cooney and Walker 1986, DiCarlo 1988, Jacobs et al. 2002, de Groot et al. 2003, El-Sayed et al. 2004, Sutbeyaz et al. 2005)
	• Increased cardiac output	Level 2	(Davis et al. 1987, Davis et al. 1991)
	• Reduced submaximal exercise heart rate	Level 4	(DiCarlo 1988)
	• Increased maximal heart rate	Level 4	(Sutbeyaz et al. 2005)
	• Increased stroke volume	Level 2	(Davis et al. 1987, Davis et al. 1991)
	• Decreased total peripheral resistance	Level 2	(Davis et al. 1987, Davis et al. 1991)
	• Increased power output	Level 1b	(Cooney and Walker 1986, DiCarlo 1988, Hjeltnes and Wallberg-Henriksson 1998, Jacobs et al. 2002, de Groot et al. 2003, Hicks et al. 2003, Sutbeyaz et al. 2005)
Lipid lipoprotein profile	• Intrinsic cellular adaptations that facilitate oxidative metabolism	Level 4	(Stewart et al. 2004)
	• Increased HDL cholesterol	Level 2	(Hooker and Wells 1989, Nash et al. 2001, El-Sayed and Younesian 2005)
	• Reduced LDL cholesterol	Level 1	(Hooker and Wells 1989, Nash et al. 2001, de Groot et al. 2003, Stewart et al. 2004)
	• Reduced triglycerides	Level 1b	(de Groot et al. 2003)
Glucose homeostasis	• Increased insulin sensitivity, decreased insulin resistance, and/or improved glucose tolerance.	Level 1b	(de Groot et al. 2003)

Note: HDL = high-density lipoprotein; LDL = low-density lipoprotein.